NovoCure Limited Price Today
NovoCure Limited
NVCR
Healthcare
$3.03B
💰
Market Cap
0
💸
Price to Earnings
$-1.4
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
6 |
Strong Buy |
2 |
Hold |
3 |
Sell |
1 |
Strong Sell |
0 |
NVCR Price Forecast Target
28.6 👉 200.0 +601%
NVCR EPS Forecast
-1.4 👉 -6.2 +353%
Financials
Profit Margin
-34 %
Revenue Growth
-10.5 %
Dividend
$ 0
Held Percent
1.2% - Insiders
85.6% - Institutions
13.2% - Public
Major Fund Holders
-
💰 FMR, LLC $950.5M
-
💰 Capital World Investors $843.5M
-
💰 Vanguard Group Inc $584.4M
-
💰 Baillie Gifford and Company $360.7M
-
💰 Blackrock Inc. $500.7M
Stock Ideas
Charlie Munger Portfolio
Charlie Munger, the renowned investor and Vice Chairman of Berkshire Hathaway, is a true titan in the world of finance. Often referred to as Warren Buffett's right-hand man, Munger's portfolio investment approach is a masterclass in disciplined and …
Ken Griffin Portfolio
Ken Griffin, the visionary founder of Citadel Investment Group, has transformed portfolio strategy with his innovative and tech-driven approach. Starting as a college student trading stock options, Griffin quickly rose to success and attracted signi…
Paul Tudor Jones Portfolio
Paul Tudor Jones is a pioneer in macro trading and founder of Tudor Investment Corporation, one of the earliest pioneering hedge funds. With over 40 years of experience investing across global markets, Jones strategically allocates capital based on …
Daniel Loeb Portfolio
Daniel Loeb is an American billionaire businessman and founder/CEO of Third Point LLC, a global investment firm managing over $12 billion in assets through long/short equity investments and activism. As one of the world's most successful hedge fund…📮FAQ
Some Frequently Asked Questions.
The NovoCure Limited industry is Medical Devices
The NovoCure Limited sector is Healthcare
The NovoCure Limited forecasted predicted Price to Earnings PE ratio is -4.6
The NovoCure Limited Price to Earnings PE ratio is 0
The Market Capitalization of NovoCure Limited is $3.03B
There are total of 95420141 float shares with 85.6% held by Institutions and 1.2% held by insiders
The MNovoCure Limited forecasted Earnings per Share EPS is $-6.2
The NovoCure Limited Earnings per Share EPS is -1.4
The NovoCure Limited company has $423584000 gross profits with -34 profit margins
The NovoCure Limited Earnings Growth is 0% with 0% quarterly earnings growth
The NovoCure Limited Revenue is $507660000 with -0.105 revenue growth
The price target for NovoCure Limited stock is $200.0 for the high target and $33.0 for the low target
The consensus analyst recommendations for NovoCure Limited is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for NovoCure Limited is Hold, with the following breakdown:
- Buy: 6
- Strong Buy: 2
- Hold: 3
- Sell: 1
- Strong Sell: 0
The Beta of NovoCure Limited is 0.6
The dividend of NovoCure Limited is $0
The dividend yield of NovoCure Limited is 0%
The biggest institutional and mutual fund holders of NovoCure Limited stock are
- FMR, LLC
- Capital World Investors
- Vanguard Group Inc
- Baillie Gifford and Company
The NovoCure Limited ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0